These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 15048960)
21. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313 [TBL] [Abstract][Full Text] [Related]
22. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Cano G; Milanezi F; Leitão D; Ricardo S; Brito MJ; Schmitt FC Diagn Cytopathol; 2003 Oct; 29(4):207-11. PubMed ID: 14506673 [TBL] [Abstract][Full Text] [Related]
23. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399 [TBL] [Abstract][Full Text] [Related]
24. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. Adams AL; Eltoum I; Krontiras H; Wang W; Chhieng DC Breast J; 2008; 14(2):141-6. PubMed ID: 18248553 [TBL] [Abstract][Full Text] [Related]
25. Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing. Benevolo M; Vocaturo A; Novelli F; Mariani L; Vocaturo G; Cianciulli AM; Marandino F; Perrone-Donnorso R; Giannarelli D; Natali PG; Mottolese M Anticancer Res; 2007; 27(4C):2839-44. PubMed ID: 17695457 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis. Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031 [TBL] [Abstract][Full Text] [Related]
27. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
28. Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression. Umekita Y; Souda M; Ohi Y; Sagara Y; Rai Y; Takahama T; Yoshida H Pathol Int; 2006 Aug; 56(8):423-7. PubMed ID: 16872435 [TBL] [Abstract][Full Text] [Related]
29. Identification of a basal-like subtype of breast ductal carcinoma in situ. Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468 [TBL] [Abstract][Full Text] [Related]
30. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer. Stefano R; Agostara B; Calabrò M; Campisi I; Ravazzolo B; Traina A; Miele M; Castagnetta L Ann N Y Acad Sci; 2004 Dec; 1028():463-72. PubMed ID: 15650272 [TBL] [Abstract][Full Text] [Related]
31. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event. Hanna W; Nofech-Mozes S; Kahn HJ Breast J; 2007; 13(2):122-9. PubMed ID: 17319852 [TBL] [Abstract][Full Text] [Related]
32. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Barnes PJ; Boutilier R; Chiasson D; Rayson D Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445 [TBL] [Abstract][Full Text] [Related]
33. Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma. Delgallo WD; Rodrigues JR; Bueno SP; Viero RM; Soares CT Cytopathology; 2010 Aug; 21(4):259-66. PubMed ID: 19843143 [TBL] [Abstract][Full Text] [Related]
34. Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer. Horiguchi J; Koibuchi Y; Iijima K; Yoshida T; Takata D; Rokutanda N; Nagaoka R; Oyama T; Iino Y; Morishita Y Oncol Rep; 2005 Nov; 14(5):1109-16. PubMed ID: 16211272 [TBL] [Abstract][Full Text] [Related]
35. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Burge CN; Chang HR; Apple SK Breast; 2006 Apr; 15(2):167-72. PubMed ID: 16095904 [TBL] [Abstract][Full Text] [Related]
36. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression. Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840 [TBL] [Abstract][Full Text] [Related]
37. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090 [TBL] [Abstract][Full Text] [Related]
38. Changes in tumour biological markers during primary systemic chemotherapy (PST). Neubauer H; Gall C; Vogel U; Hornung R; Wallwiener D; Solomayer E; Fehm T Anticancer Res; 2008; 28(3B):1797-804. PubMed ID: 18630463 [TBL] [Abstract][Full Text] [Related]
39. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090 [TBL] [Abstract][Full Text] [Related]
40. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy. Prisack HB; Karreman C; Modlich O; Audretsch W; Danae M; Rezai M; Bojar H Anticancer Res; 2005; 25(6C):4615-21. PubMed ID: 16334152 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]